Why a Smaller Response Does Not Identify Its Cause
When a drug appears to have less effect after repeated treatment, the observed response alone cannot show why. The body may have lower drug exposure under the same regimen, or the same exposure may produce a smaller response. These are different explanations, and distinguishing them matters: an exposure change calls for a different interpretation than a change in response sensitivity. Both can occur together.
The comparison must therefore use both pharmacokinetic (PK) and pharmacodynamic (PD) information. In particular, compare response at matched relevant concentrations, not merely response before and after treatment. A concentration measured in plasma is often useful, but it is not automatically the concentration driving the response. Depending on the drug and endpoint, unbound concentration, an active metabolite, or concentration at the effect site may be more relevant.
Here, \(C\) denotes the relevant concentration or exposure measure and \(R\) denotes a consistently defined drug response. For an inhibitory effect, \(R\) can be defined as the magnitude of inhibition so that a larger value always means a larger drug effect. Let \(R_B(C)\) be the response-versus-concentration relationship in a baseline period and \(R_T(C)\) the relationship during repeated treatment. A PK change concerns the exposure achieved under a comparable regimen; a PD change concerns a difference between \(R_B(C)\) and \(R_T(C)\) at the same \(C\).
Conditions for a Meaningful Paired Comparison
A paired comparison follows the same individual, or the same well-defined study group, across periods. Pairing helps control stable differences between people, but it does not remove time-varying confounding or make unlike measurements comparable. Before classifying tolerance, check the following:
- Comparable regimen and administration. Dose, formulation, dosing interval, adherence, and sampling relative to dosing should be known. A lower concentration after a dose reduction is not evidence of PK tolerance.
- Comparable exposure measurement. Use concentrations or exposure summaries appropriate to the response, such as concentration at a specified time or area under the concentration-time curve (AUC) over a defined interval. Check assay comparability and whether active metabolites or unbound drug matter.
- Comparable response definition and baseline. Use the same endpoint, scale, measurement method, and clinically meaningful direction. Account for baseline response changes that could make a raw response difference look like a drug-effect difference.
- Comparable time course. A delayed concentration–effect relationship can make the same plasma concentration correspond to different responses during rising and falling concentration phases. Match sampling phase or relevant concentration history; a single matched plasma concentration may not be enough.
- Adequate overlap in exposure. The periods need concentrations in common to compare response directly. If the chronic-period observations lie outside the baseline range, the matched-exposure comparison requires extrapolation and is less secure.
A lower AUC under the same regimen supports an exposure decrease, but does not by itself identify its cause. For example, apparent clearance calculated as dose divided by AUC depends on bioavailability as well as clearance. Likewise, a lower response at one matched concentration supports a PD difference only if the concentration is a suitable driver and relevant history, baseline, and other time-varying influences have been considered.
Separating Exposure Change From Response Change
The logic can be made explicit by separating the observed response difference into two parts. Suppose the baseline-period concentration is \(C_B\) and the treatment-period concentration is \(C_T\). If the response functions can be evaluated at these concentrations, then:
The first bracket is the response difference predicted from the exposure shift alone, using the baseline response relationship. The second bracket is the response difference between periods at the treatment-period concentration: a matched-exposure PD contrast. Their sum equals the observed response difference by adding and subtracting \(R_B(C_T)\). This is an algebraic decomposition, not proof that exposure change caused the first component or that a specific mechanism caused the second.
The decomposition depends on the order chosen. One could instead compare the periods at \(C_B\), assigning the PD contrast at baseline concentration and the exposure contrast to the treatment-period response curve. If the concentration-response relationships are not parallel, these decompositions need not give the same component sizes. Report the chosen reference period and concentration, and avoid treating the components as uniquely defined causal effects without additional assumptions.
Worked Example: An Exposure Decline With No Matched-Exposure Shift
The following hypothetical measurements come from one participant receiving the same 100 mg dose and dosing interval in both periods. AUC over the dosing interval is 100 \(\mu\text{g}\cdot\text{h}/\text{L}\) at baseline and 70 \(\mu\text{g}\cdot\text{h}/\text{L}\) after repeated treatment. At comparable sampling phases, the response magnitude is 61.5 units when concentration is 8 \(\mu\text{g}/\text{L}\), and 50.0 units when concentration is 5 \(\mu\text{g}/\text{L}\). Paired observations across periods show the same response at shared concentrations.
Exposure change. The percentage AUC decrease is
Thus, measured exposure is 30.0% lower on the same stated regimen. This supports a PK-tolerance pattern, provided dosing, adherence, sampling, and the AUC interval are comparable.
Response check. The lower observed concentration is accompanied by a smaller response: \(61.5-50.0=11.5\) response units. But that comparison is across different concentrations. Because the paired concentration-response observations agree at shared concentrations, the data shown do not indicate a reduced response at matched exposure. The appropriate conclusion is an exposure decrease without evidence here of a PD shift—not proof that no PD change exists anywhere on the response curve.
The example assumes that the reported concentration is a suitable response driver and that the response is compared at comparable times in the concentration–effect course. If those assumptions fail, apparent agreement at matched plasma concentrations may be misleading.
Reading Paired Concentration-Response Comparisons
For a direct PD assessment, compare response measurements from the two periods at the same relevant concentration, preferably across several concentrations. A difference at a single concentration is local evidence; several shared concentrations show whether the pattern is consistent across the observed range. A fitted concentration-response curve can summarize the relationship, but it should not be used to conceal weak overlap, sparse observations, or systematic differences in sampling.
For example, a simple saturable relationship might be used as a descriptive approximation:
Here \(R_0\) is the response at zero concentration, \(R_{\max}\) is the maximum additional response in this model, and \(EC_{50}\) is the concentration producing half of that maximum additional response. The equation can help interpolate between measured concentrations, but it is not required for the basic comparison and does not establish a mechanism. Use it only when its shape is plausible and the data support estimating its parameters.
Worked Example: Reduced Response at Matched Concentrations
In a hypothetical paired assessment, the endpoint is response magnitude in units, with larger values representing a stronger drug effect. Measurements at three shared concentrations are:
| Concentration (\(\text{mg}/\text{L}\)) | Baseline response (units) | Repeated-treatment response (units) |
|---|---|---|
| 2 | 28 | 20 |
| 5 | 50 | 35 |
| 10 | 67 | 50 |
At \(5\ \text{mg}/\text{L}\), the paired response difference, defined as baseline minus repeated-treatment response, is
At the other shared concentrations, the corresponding differences are \(28-20=8\) units and \(67-50=17\) units. The response is lower during repeated treatment at each of the three matched concentrations. If concentration, timing, baseline adjustment, and response measurement are comparable, this pattern supports a PD-tolerance classification over the observed concentration range.
The table alone does not show that every person has the same change, nor does it establish why the response relationship changed. In a population analysis, show the paired individual data and quantify uncertainty; do not treat these illustrative values as a population estimate.
When Both Components May Be Present
The categories are not mutually exclusive. Exposure can decline and response at matched exposure can also decline. The decomposition below illustrates both components using hypothetical data. Suppose the same regimen gives baseline AUC \(120\ \mu\text{g}\cdot\text{h}/\text{L}\) and repeated-treatment AUC \(90\ \mu\text{g}\cdot\text{h}/\text{L}\). At baseline concentration \(8\ \text{mg}/\text{L}\), baseline response is 60 units. At the repeated-treatment concentration \(4\ \text{mg}/\text{L}\), baseline response would be 40 units, while repeated-treatment response is 30 units.
The AUC decrease is
The total observed response difference is \(60-30=30\) units. Using the baseline curve as the reference, its exposure component is \(60-40=20\) units, and its matched-exposure PD component is \(40-30=10\) units. The arithmetic checks:
This pattern is consistent with both lower exposure and a smaller response at the repeated-treatment concentration. The numerical division is reference-dependent, as described above; the direct findings—lower AUC and lower response at a shared concentration—are more fundamental than the particular component sizes.
Diagnostics, Alternatives, and Common Pitfalls
Plot paired concentration-response observations by period, using a consistent response scale and identifying whether points are from the same individuals. Also examine concentration-time profiles and sampling times. A curve separation that disappears after correcting a baseline shift, or that appears only on one concentration phase, calls for caution. Limited overlap, assay changes, missing observations, or a changing disease state can all make a nominally matched comparison uninformative.
A comparison of dose-normalized AUC or concentration summaries is useful for detecting an exposure change, but it cannot establish PD tolerance. A comparison of raw response before and after treatment is simpler, but cannot separate PK from PD. Paired concentration-response comparisons address the key distinction directly, while model-based joint PK/PD analysis can use more of the time-course information. Such models add assumptions and can be poorly identified when concentrations do not overlap or response sampling is sparse; they are not a substitute for checking the observed data.
Common mistake: “The response fell by 20%, so the patient developed pharmacodynamic tolerance.” This conclusion compares responses without checking exposure. If concentration also fell, the response reduction may be explained partly or entirely by lower exposure. The correction is to compare exposure under a comparable regimen and then compare response at matched relevant exposure, accounting for timing and baseline. A lower response at matched concentration is evidence for a PD difference, not by itself proof of a particular biological cause.
The classification has limits. Plasma concentration may not represent unbound or effect-site concentration; response may depend on recent exposure history; and disease progression or co-medication may change the endpoint independently of the drug. When these concerns cannot be resolved, report the pattern as uncertain rather than assigning a definitive PK-only or PD-only label.
Check Your Understanding
For each question, consider what can and cannot be concluded from the stated comparison. Solutions follow each question.
- A patient receives the same regimen in both periods. AUC falls from 80 to 60 \(\text{mg}\cdot\text{h}/\text{L}\). What is the percentage decrease, and what does it support? Solution: \((80-60)/80\times100\%=25.0\%\). With comparable dosing and measurement, this supports an exposure decline and a PK-tolerance pattern; it does not identify the mechanism.
- At a shared concentration of \(3\ \text{mg}/\text{L}\), response is 24 units at baseline and 18 units during repeated treatment. What is the matched-exposure difference? Solution: Baseline minus repeated-treatment response is \(24-18=6\) units. This supports a lower response at that matched concentration if timing, baseline, and concentration relevance are comparable.
- Why is a response of 40 units at \(8\ \text{mg}/\text{L}\) not directly comparable to 25 units at \(4\ \text{mg}/\text{L}\) as evidence of PD tolerance? Solution: Concentrations differ, so the response difference may result from the exposure difference. Compare responses at shared concentrations or use a justified model to estimate them within common support.
- Baseline and repeated-treatment concentration-response curves overlap at shared concentrations, but AUC is lower during repeated treatment under the same regimen. Which pattern is supported? Solution: An exposure decline without evidence of a matched-exposure response shift in the observed range. This supports a PK pattern, while not proving that PD tolerance is absent outside the measured range.
- Why might the same measured plasma concentration correspond to different responses during rising and falling concentrations? Solution: The effect may lag behind plasma concentration or depend on recent concentration history. Match sampling phase or relevant exposure history, or interpret a single-concentration comparison cautiously.